Objective: To assess whether 17 alpha-hydroxyprogesterone caproate reduces the rate of preterm birth in women carrying triplets.
Methods: We performed this randomized, double-blinded, placebo-controlled trial in 14 centers. Healthy women with triplets were randomly assigned to weekly intramuscular injections of either 250 mg of 17 alpha-hydroxyprogesterone caproate or matching placebo, starting at 16-20 weeks and ending at delivery or 35 weeks of gestation. The primary study outcome was delivery or fetal loss before 35 weeks.
Results: One hundred thirty-four women were assigned, 71 to 17 alpha-hydroxyprogesterone caproate and 63 to placebo; none were lost to follow-up. Baseline demographic data were similar in the two groups. The proportion of women experiencing the primary outcome (a composite of delivery or fetal loss before 35 0/7 weeks) was similar in the two treatment groups: 83% of pregnancies in the 17 alpha-hydroxyprogesterone caproate group and 84% in the placebo group, relative risk 1.0, 95% confidence interval 0.9-1.1. The lack of benefit of 17 alpha-hydroxyprogesterone caproate was evident regardless of the conception method or whether a gestational age cutoff for delivery was set at 32 or 28 weeks.
Conclusion: Treatment with 17 alpha-hydroxyprogesterone caproate did not reduce the rate of preterm birth in women with triplet gestations.
Clinical Trial Registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00099164
Level Of Evidence: I.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790283 | PMC |
| http://dx.doi.org/10.1097/AOG.0b013e318193c677 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaginal progesterone for prevention of preterm birth in women with a history of preterm birth regardless of cervical length: an argument against use.
Am J Obstet Gynecol MFM
November 2024
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke Health, Durham, NC.
Article Synopsis
- - Preterm birth occurs before 37 weeks of gestation and is a leading cause of neonatal and early infant death, making it a critical public health issue.
- - While progesterone supplementation, particularly 17-alpha hydroxyprogesterone caproate, was initially seen as a potential solution for reducing preterm birth risk, its approval was revoked due to limited effectiveness.
- - Recent meta-analyses indicate that vaginal progesterone does not significantly lower the rates of recurring preterm birth in women with previous preterm deliveries, suggesting that its universal use for this purpose may not be justified.
Vaginal administration of 17-alpha hydroxyprogesterone caproate appears to be safe in non-pregnant female rats and rabbits.
Xenobiotica
October 2024
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Intramuscular (250 mg once weekly) or subcutaneous (275 mg once weekly) injections of 17-hydroxyprogesterone caproate (17-OHPC) has been utilised to prevent recurent spontaneous preterm birth in pregnant women with a short cervix or those with a prior preterm birth but its efficacy in these conditions has been questioned. It is unclear whether adequate concentrations of 17-OHPC reach the suspected target organs such as the cervix and uterus following either IM or SC administration.The objective of this study was to determine feasibility and safety of vaginal administration of 17-OHPC in adult female Sprague Dawley rats and female New Zealand rabbits.
View Article and Find Full Text PDFDevelopmental 17-OHPC exposure disrupts behavior regulated by the mesocorticolimbic dopaminergic system in rats.
Pharmacol Biochem Behav
December 2024
Department of Psychology & Center for Neuroscience Research, University at Albany, Albany, NY, USA.
The synthetic progestin, 17α-hydroxyprogesterone caproate (17-OHPC), is administered to pregnant individuals with the intention of reducing preterm birth. Although there is evidence that 17-OHPC is likely transferred from mother to fetus, there is little information regarding the potential effects of 17-OHPC administration on behavioral and neural development in offspring. Neonatal 17-OHPC exposure disrupts the development of the mesocorticolimbic dopaminergic pathway and associated behaviors in rats.
View Article and Find Full Text PDFImplications of Developmental 17-OHPC Exposure on the Mesocorticolimbic Serotonergic and Dopaminergic Pathways and Adolescent Mood-Related Behavior in Rats.
Dev Psychobiol
September 2024
Department of Psychology & Center for Neuroscience Research, University at Albany, Albany, New York, USA.
The synthetic progestin, 17-α-hydroxyprogesterone caproate (17-OHPC), is administered to pregnant individuals at risk for recurrent preterm birth during a critical period of fetal mesocorticolimbic serotonergic and dopaminergic pathway development. These pathways play an important role in regulating cognitive behaviors later in life. Despite this, there has been very little research regarding the potential long-term effects of 17-OHPC on the behavioral and neural development of exposed children.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!